Advanced

TFPI-2 protects against gram-negative bacterial infection

Ali, Mohamad N. LU ; Kasetty, Gopinath LU ; Elvén, Malin LU ; Alyafei, Saud; Jovic, Sandra LU ; Egesten, Arne LU ; Herwald, Heiko LU ; Schmidtchen, Artur LU and Papareddy, Praveen LU (2018) In Frontiers in Immunology 9(SEP).
Abstract

Tissue factor pathway inhibitor-2 (TFPI-2) has previously been characterized as an endogenous anticoagulant. TFPI-2 is expressed in the vast majority of cells, mainly secreted into the extracellular matrix. Recently we reported that EDC34, a C-terminal peptide derived from TFPI-2, exerts a broad antimicrobial activity. In the present study, we describe a previously unknown antimicrobial mode of action for the human TFPI-2 C-terminal peptide EDC34, mediated via binding to immunoglobulins of the classes IgG, IgA, IgE, and IgM. In particular the interaction of EDC34 with the Fc part of IgG is of importance since this boosts interaction between the immunoglobulin and complement factor C1q. Moreover, we find that the binding increases the... (More)

Tissue factor pathway inhibitor-2 (TFPI-2) has previously been characterized as an endogenous anticoagulant. TFPI-2 is expressed in the vast majority of cells, mainly secreted into the extracellular matrix. Recently we reported that EDC34, a C-terminal peptide derived from TFPI-2, exerts a broad antimicrobial activity. In the present study, we describe a previously unknown antimicrobial mode of action for the human TFPI-2 C-terminal peptide EDC34, mediated via binding to immunoglobulins of the classes IgG, IgA, IgE, and IgM. In particular the interaction of EDC34 with the Fc part of IgG is of importance since this boosts interaction between the immunoglobulin and complement factor C1q. Moreover, we find that the binding increases the C1q engagement of the antigen-antibody interaction, leading to enhanced activation of the classical complement pathway during bacterial infection. In experimental murine models of infection and endotoxin challenge, we show that TFPI-2 is up-regulated in several organs, including the lung. Correspondingly, TFPI-2-/- mice are more susceptible to pulmonary Pseudomonas aeruginosa bacterial infection. No anti-coagulant role of TFPI-2 was observed in these models in vivo. Furthermore, in vivo, the mouse TFPI-2-derived C-terminal peptide VKG24, a homolog to human EDC34 is protective against systemic Escherichia coli bacterial infection. Moreover, in sputum from cystic fibrosis patients TFPI-2 C-terminal fragments are generated and found associated with immunoglobulins. Together our data describe a previously unknown host defense mechanism and therapeutic importance of TFPI-2 against invading Gram-negative bacterial pathogens.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Antimicrobial peptide, Bacteria, Complement, Immunoglobulins, Sepsis, TFPI-2
in
Frontiers in Immunology
volume
9
issue
SEP
publisher
Frontiers Media S. A.
external identifiers
  • scopus:85053133750
ISSN
1664-3224
DOI
10.3389/fimmu.2018.02072
language
English
LU publication?
yes
id
3655c179-c2b8-4111-9a49-8b658034c465
date added to LUP
2018-10-11 11:07:46
date last changed
2019-09-04 02:21:00
@article{3655c179-c2b8-4111-9a49-8b658034c465,
  abstract     = {<p>Tissue factor pathway inhibitor-2 (TFPI-2) has previously been characterized as an endogenous anticoagulant. TFPI-2 is expressed in the vast majority of cells, mainly secreted into the extracellular matrix. Recently we reported that EDC34, a C-terminal peptide derived from TFPI-2, exerts a broad antimicrobial activity. In the present study, we describe a previously unknown antimicrobial mode of action for the human TFPI-2 C-terminal peptide EDC34, mediated via binding to immunoglobulins of the classes IgG, IgA, IgE, and IgM. In particular the interaction of EDC34 with the Fc part of IgG is of importance since this boosts interaction between the immunoglobulin and complement factor C1q. Moreover, we find that the binding increases the C1q engagement of the antigen-antibody interaction, leading to enhanced activation of the classical complement pathway during bacterial infection. In experimental murine models of infection and endotoxin challenge, we show that TFPI-2 is up-regulated in several organs, including the lung. Correspondingly, TFPI-2<sup>-/-</sup> mice are more susceptible to pulmonary Pseudomonas aeruginosa bacterial infection. No anti-coagulant role of TFPI-2 was observed in these models in vivo. Furthermore, in vivo, the mouse TFPI-2-derived C-terminal peptide VKG24, a homolog to human EDC34 is protective against systemic Escherichia coli bacterial infection. Moreover, in sputum from cystic fibrosis patients TFPI-2 C-terminal fragments are generated and found associated with immunoglobulins. Together our data describe a previously unknown host defense mechanism and therapeutic importance of TFPI-2 against invading Gram-negative bacterial pathogens.</p>},
  articleno    = {2072},
  author       = {Ali, Mohamad N. and Kasetty, Gopinath and Elvén, Malin and Alyafei, Saud and Jovic, Sandra and Egesten, Arne and Herwald, Heiko and Schmidtchen, Artur and Papareddy, Praveen},
  issn         = {1664-3224},
  keyword      = {Antimicrobial peptide,Bacteria,Complement,Immunoglobulins,Sepsis,TFPI-2},
  language     = {eng},
  month        = {09},
  number       = {SEP},
  publisher    = {Frontiers Media S. A.},
  series       = {Frontiers in Immunology},
  title        = {TFPI-2 protects against gram-negative bacterial infection},
  url          = {http://dx.doi.org/10.3389/fimmu.2018.02072},
  volume       = {9},
  year         = {2018},
}